Evidence map›Paper›PMID 35290421›Full record

ArticlePloS one2022

Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekwini, South Africa, 2016-2020.

Amrita Rao, Hlengiwe Mhlophe, Carly Comins, Katherine Young, Mfezi Mcingana, Catherine Lesko, Ntambue Mulumba, Stefan Baral, Harry Hausler, Sheree Schwartz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. There is no path to ending AIDS by 2030 without improving human rights.Journal of the International AIDS Society · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Amrita RaoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0002-9596-2418
Hlengiwe MhlopheTB HIV Care, Durban, South Africa.
Carly CominsDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Katherine YoungTB HIV Care, Cape Town, South Africa.
Mfezi McinganaTB HIV Care, Cape Town, South Africa.
Catherine LeskoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0002-1717-2592
Ntambue MulumbaTB HIV Care, Durban, South Africa.
Stefan BaralDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Harry HauslerTB HIV Care, Cape Town, South Africa.
Sheree SchwartzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Johns Hopkins University · USRight to Care · ZA

Funding

Examining PrEP use, implementation preferences and the potential for social support to improve PrEP delivery and persistence among female sex workers in Durban, South AfricaR01NR016650 · NINR · JOHNS HOPKINS UNIVERSITY · PI BARAL, STEFAN DAVID · 2016 to 2020
$3.2M
PrEP among high-risk young women in South Africa: real-world barriers to use and patterns of re-initiation and PrEP cyclingF31MH124458 · NIMH · JOHNS HOPKINS UNIVERSITY · PI RAO, AMRITA · 2020 to 2021
$86k
NIMH NIH HHS F31 MH124458NINR NIH HHS R01 NR016650
6 · The paper itself

Abstract

backgroundDespite the established efficacy of PrEP to prevent HIV and the advantages of a user-controlled method, PrEP uptake and persistence by women in both trials and demonstration projects has been suboptimal. We utilized real-world data from an HIV service provider to describe persistence on oral PrEP among female sex workers (FSW) in eThekwini, South Africa.

methodsWe examined time from PrEP initiation to discontinuation among all FSW initiating PrEP at TB HIV Care in eThekwini between 2016-2020. We used a discrete time-to-event data setup and stacked cumulative incidence function plots, displaying the competing risks of 1) not returning for PrEP, 2) client discontinuation, and 3) provider discontinuation. We calculated hazard ratios using complementary log-log regression and sub-hazard ratios using competing risks regression.

resultsThe number of initiations increased each year from 155 (9.3%, n = 155/1659) in 2016 to 1224 (27.5%, n = 1224/4446) in 2020. Persistence 1-month after initiation was 53% (95% CI: 51%-55%). Younger women were more likely to discontinue PrEP by not returning compared with those 25 years and older. Risk of discontinuation through non-return declined for those initiating in later years. Despite the COVID-19 pandemic, a greater number of initiations and sustained persistence were observed in 2020.

conclusionsLow levels of PrEP persistence were observed, consistent with data among underserved women elsewhere. Encouragingly, the proportion of women persisting increased over time, even as the number of women newly initiating PrEP and staff workload increased. Further research is needed to understand which implementation strategies the program may have enacted to facilitate these improvements and what further changes may be necessary.

Indexed as

Drug MonitoringAdministration, OralAdultAnti-HIV AgentsFemaleHIV InfectionsHumansMedication AdherencePre-Exposure ProphylaxisSex WorkersSouth AfricaYoung AdultAnti-HIV Agents

Identifiers

PMID35290421
PMCPMC8923438
OpenAlexW4220957437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.